Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study, PMID: 31506387
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study, PMID: 27932068
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate, PMID: 30232719
DLL3: an emerging target in small cell lung cancer, PMID: 31215500
Precision medicine for human cancers with Notch signaling dysregulation (Review), PMID: 31894255
Treatment advances in small cell lung cancer (SCLC), PMID: 28579387
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer, PMID: 33340277
Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine, PMID: 31148500
Drugs in development for small cell lung cancer, PMID: 33209468
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer, PMID: 33257843
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer, PMID: 30894499
Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer, PMID: 27932065
Phototoxic drug reaction with the novel agent rovalpituzumab tesirine, PMID: 29319846
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC, PMID: 34425994
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer, PMID: 31446987
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study, PMID: 33823285
[Small Cell Lung Cancer], PMID: 29486510
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study, PMID: 33607312
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC, PMID: 33652156
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC, PMID: 34242790
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors, PMID: 34354225
Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer, PMID: 31981983
Advances in antibody therapeutics targeting small-cell lung cancer, PMID: 29790694
Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma, PMID: 30543588
Progress in the Management of Advanced Thoracic Malignancies in 2017, PMID: 29331646
Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma, PMID: 32372416
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments, PMID: 29116596
ADC Shows Effectiveness in SCLC, PMID: 26493959
Progress and challenges in the treatment of small cell lung cancer, PMID: 28456992
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer, PMID: 34329846
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy, PMID: 32543981
Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer, PMID: 28778960
Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies, PMID: 32267477
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges, PMID: 30968324
Current and future therapeutic approaches for the treatment of small cell lung cancer, PMID: 29544351
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?], PMID: 30100047
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload, PMID: 27882195
Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression, PMID: 33074129
Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer, PMID: 31412616
What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016, PMID: 28685608
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer, PMID: 28487384
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702), PMID: 31068386
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer, PMID: 29290251
The clinical conundrum of managing relapsed small cell lung cancer, PMID: 30561759
Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors, PMID: 31447005
Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview, PMID: 34107132
Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer, PMID: 31452726
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma, PMID: 30397180
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies, PMID: 29088717
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer, PMID: 29435295
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer., PMID:40177519
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions., PMID:39703856
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models., PMID:39143619
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial., PMID:38950555
FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models., PMID:38940283
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy., PMID:38730427
Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates., PMID:38001628
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons., PMID:36530878
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma., PMID:36381237
Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity., PMID:36034078
Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study., PMID:35795565
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer., PMID:34942494
Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair., PMID:34924498
Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples., PMID:34692726
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC., PMID:34425994
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors., PMID:34354225
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer., PMID:34329846
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC., PMID:34242790
Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview., PMID:34107132
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study., PMID:33823285
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC., PMID:33652156
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study., PMID:33607312
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer., PMID:33340277
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer., PMID:33257843
Drugs in development for small cell lung cancer., PMID:33209468
Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression., PMID:33074129
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy., PMID:32543981
Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma., PMID:32372416
Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies., PMID:32267477
Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer., PMID:31981983
Precision medicine for human cancers with Notch signaling dysregulation (Review)., PMID:31894255
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study., PMID:31506387
Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer., PMID:31452726
Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors., PMID:31447005
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer., PMID:31446987
Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer., PMID:31412616
DLL3: an emerging target in small cell lung cancer., PMID:31215500
Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine., PMID:31148500
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)., PMID:31068386
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges., PMID:30968324
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer., PMID:30894499
The clinical conundrum of managing relapsed small cell lung cancer., PMID:30561759
Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma., PMID:30543588
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma., PMID:30397180
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate., PMID:30232719
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]., PMID:30100047
Advances in antibody therapeutics targeting small-cell lung cancer., PMID:29790694
Current and future therapeutic approaches for the treatment of small cell lung cancer., PMID:29544351
For research use only. Not for human or drug use.
